GLG Partners LP purchased a new position in Innocoll Holdings PLC (NASDAQ:INNL) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 87,600 shares of the specialty pharmaceutical company’s stock, valued at approximately $200,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Gamco Investors INC. ET AL bought a new position in Innocoll Holdings PLC in the second quarter worth approximately $285,000. Deltec Asset Management LLC bought a new position in Innocoll Holdings PLC in the second quarter worth approximately $296,000. Goldman Sachs Group Inc. bought a new position in Innocoll Holdings PLC in the first quarter worth approximately $224,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Innocoll Holdings PLC in the second quarter worth approximately $802,000. Finally, Tudor Investment Corp ET AL bought a new position in Innocoll Holdings PLC in the second quarter worth approximately $868,000. Institutional investors and hedge funds own 34.16% of the company’s stock.

Innocoll Holdings PLC (NASDAQ INNL) opened at 2.35 on Thursday. The firm has a 50-day moving average of $2.25 and a 200 day moving average of $1.58. Innocoll Holdings PLC has a 52-week low of $0.53 and a 52-week high of $6.51.

COPYRIGHT VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/glg-partners-lp-takes-200000-position-in-innocoll-holdings-plc-innl.html.

Separately, FBR & Co reiterated a “hold” rating on shares of Innocoll Holdings PLC in a research report on Tuesday, July 4th.

Innocoll Holdings PLC Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.

Want to see what other hedge funds are holding INNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innocoll Holdings PLC (NASDAQ:INNL).

Institutional Ownership by Quarter for Innocoll Holdings PLC (NASDAQ:INNL)

Receive News & Stock Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related stocks with our FREE daily email newsletter.